Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People treated with Biktarvy were more likely to achieve an undetectable HBV viral load than those on a dolutegravir-based regimen.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.
The World Health Organization (WHO) has added a new hepatitis C treatment to its updated 2017 Essential Medicines List.
Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.
Researchers presented results from various studies on hepatitis C treatment and care at a medical conference in Seattle.
People who coinfected with HIV and hepatitis C looking to take the HCV drug Olysio may need to change HIV medications to avoid drug-drug inte...
The looming threat of a government shutdown on October 1 may spell potential delays in FDA approvals of new drugs.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.